{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:14:01Z","timestamp":1790802841507,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.bioorg.2020.103616","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T11:20:34Z","timestamp":1579951234000},"page":"103616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10\/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology"],"prefix":"10.1016","volume":"96","author":[{"given":"El Sayed Helmy","family":"El Ashry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila Fathy","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Teleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal Ahmed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa M.","family":"Abu-Serie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Nabil","family":"Abd Al Moaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.103616_b0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrm2125","article-title":"Matrix metalloproteinases and the regulation of tissue remodelling","volume":"8","author":"Page-McCaw","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2020.103616_b0010","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cardiores.2005.12.002","article-title":"Structure and function of matrix metalloproteinases and TIMPs","volume":"69","author":"Nagase","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bioorg.2020.103616_b0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.cellbio.17.1.463","article-title":"How matrix metalloproteinases regulate cell behavior","volume":"17","author":"Sternlicht","year":"2001","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2020.103616_b0020","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry","volume":"92","author":"Visse","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.bioorg.2020.103616_b0025","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1021\/cr9804543","article-title":"Design and therapeutic application of matrix metalloproteinase inhibitors","volume":"99","author":"Whittaker","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2020.103616_b0030","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2174\/138161207781039706","article-title":"Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors","volume":"13","author":"Nuti","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2020.103616_b0035","doi-asserted-by":"crossref","first-page":"21491","DOI":"10.1074\/jbc.274.31.21491","article-title":"Matrix metalloproteinases","volume":"274","author":"Nagase","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2020.103616_b0040","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jmb.2003.12.033","article-title":"Crystal structure of the catalytic domain of human matrix metalloproteinase 10","volume":"336","author":"Bertini","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"3\u20134","key":"10.1016\/j.bioorg.2020.103616_b0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.biochi.2004.11.019","article-title":"Crystal structures of MMPs in complex with physiological and pharmacological inhibitors","volume":"87","author":"Maskos","year":"2005","journal-title":"Biochimie"},{"key":"10.1016\/j.bioorg.2020.103616_b0050","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2009.23.5556","article-title":"Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer","volume":"27","author":"Roy","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2020.103616_b0055","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd4390","article-title":"Is there new hope for therapeutic matrix metalloproteinase inhibition?","volume":"13","author":"Vandenbroucke","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2020.103616_b0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1593\/neo.04283","article-title":"MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas","volume":"6","author":"Gill","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.bioorg.2020.103616_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025438","article-title":"MMP-10\/stromelysin-2 promotes invasion of head and neck cancer","volume":"6","author":"Deraz","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2020.103616_b0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/10409230290771483","article-title":"The structure, regulation, and function of human matrix metalloproteinase-13","volume":"37","author":"Leeman","year":"2002","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2020.103616_b0075","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0361-090X(02)00035-1","article-title":"Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications","volume":"26","author":"Mathew","year":"2002","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.bioorg.2020.103616_b0080","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.4049\/jimmunol.173.6.3605","article-title":"Stromelysin-2 (matrix metalloproteinase 10) is inducible in lymphoma cells and accelerates the growth of lymphoid tumors in vivo","volume":"173","author":"Van Themsche","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2020.103616_b0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/s10165-004-0292-7","article-title":"Ten years in the life of an enzyme: the story of the human MMP-13 (Collagenase-3)","volume":"14","author":"Tardif","year":"2004","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.bioorg.2020.103616_b0090","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1002\/art.22167","article-title":"MatrixMetalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis","volume":"54","author":"Barksby","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bioorg.2020.103616_b0095","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2174\/092986711794940905","article-title":"New hope for the treatment of osteoarthritis through selective inhibition of MMP-13","volume":"18","author":"Li","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0100","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1161\/ATVBAHA.111.231563","article-title":"Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis","volume":"31","author":"Quillard","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bioorg.2020.103616_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gendis.2019.02.004","article-title":"Matrix metalloproteinase 13, a new target for therapy in Alzheimer's disease","volume":"1, 6(1)","author":"Paumier","year":"2019","journal-title":"Genes Diseases."},{"key":"10.1016\/j.bioorg.2020.103616_b0110","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.1021\/acs.jmedchem.7b01001","article-title":"Targeted polypharmacology: discovery of a highly potent non-hydroxamate dual matrix metalloproteinase (MMP)-10\/-13 inhibitor","volume":"13","author":"Senn","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0115","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.1021\/jm500981k","article-title":"Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach","volume":"57","author":"Nara","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0120","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1016\/j.bmc.2014.07.025","article-title":"Thieno[2,3-d]Pyrimidine-2-Carboxamides Bearing a Carboxyben- zene Group at 5-Position: Highly Potent, Selective, and Orally Available MMP-13 Inhibitors Interacting with the S1\u2033 Binding Site","volume":"22","author":"Nara","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/open.201600158","article-title":"Targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor","volume":"6","author":"Fischer","year":"2017","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.bioorg.2020.103616_b0130","first-page":"1445","article-title":"Strategic targeting of multiple water-mediated interactions: a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors","volume":"8","author":"Fischer","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2020.103616_b0135","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/ijms17030314","article-title":"Molecular recognition of the catalytic zinc (II) Ion in MMP-13: structure-based evolution of an allosteric inhibitor to dual binding mode inhibitors with improved lipophilic ligand efficiencies","volume":"17","author":"Fischer","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2020.103616_b0140","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1021\/acs.jmedchem.7b00514","article-title":"Structure-based design and synthesis of potent and selective matrix metalloproteinase 13 inhibitors","volume":"60","author":"Choi","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0145","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/cmdc.201700349","article-title":"Recent research advances in selective matrix metalloproteinase-13 inhibitors as anti-osteoarthritis agents","volume":"12","author":"Xie","year":"2017","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.bioorg.2020.103616_b0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chembiol.2004.11.014","article-title":"Structural basis for the highly selective inhibition of MMP-13","volume":"12","author":"Engel","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2020.103616_b0155","unstructured":"C. Andrianjara, D.F. Ortwine, A.G. Pavlovsky, W.H. Roark, Matrix metalloproteinase inhibitors, 2002, Patent WO2002064080."},{"key":"10.1016\/j.bioorg.2020.103616_b0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1586\/ecp.12.74","article-title":"Polypharmacology: drug discovery for the future","volume":"6","author":"Reddy","year":"2013","journal-title":"Expert Rev. Clin. Phar."},{"issue":"3","key":"10.1016\/j.bioorg.2020.103616_b0165","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.bmc.2008.03.004","article-title":"High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate","volume":"17","author":"Lauer-Fields","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2020.103616_b0170","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/acs.jmedchem.6b01007","article-title":"Discovery of novel, highly potent, and selective matrix metalloproteinase (MMP)-13 inhibitors with a 1, 2, 4-triazol-3-yl moiety as a zinc binding group using a structure-based design approach","volume":"60","author":"Nara","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0175","first-page":"162","article-title":"Recent advances in Dimroth rearrangement. A valuable tool for synthesis of heterocycles","volume":"vol. 101","author":"El Ashry","year":"2010"},{"key":"10.1016\/j.bioorg.2020.103616_b0180","first-page":"79","article-title":"Dimroth Rearrangement. Translocation of heteroatoms in heterocyclic rings and its role in ring transformations of heterocycles","volume":"vol. 75","author":"ElAshry","year":"1999"},{"key":"10.1016\/j.bioorg.2020.103616_b0185","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3184\/030823408X327875","article-title":"The Dimroth rearrangement: synthesis and interconversion of isomeric triazolothienopyrimidines","volume":"6","author":"Hamed","year":"2008","journal-title":"J. Chem. Res."},{"key":"10.1016\/j.bioorg.2020.103616_b0190","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1071\/CH9772515","article-title":"Isomerizations in to the Dimroth rearrangement. III. The conversion of simple s-Triazolo[4,3-a]pyrimidines into their [1,5-a] Isomers","volume":"30","author":"Brown","year":"1977","journal-title":"Aust. J. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0195","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11172-006-0579-2","article-title":"Studies on mechanisms of the rearrangement of thieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidines into thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines","volume":"55","author":"Vorobev","year":"2006","journal-title":"Russ. Chem. Bull. Int. Ed."},{"key":"10.1016\/j.bioorg.2020.103616_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111875","article-title":"Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K\/AKT signaling attenuation and caspase 3\/7 activation via Ugi bis-amide synthesis","volume":"186","author":"Ayoup","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0205","series-title":"Global and regional estimates of the incidence and mortality for 38 cancers: GLOBOCAN 2018","author":"Ferlay","year":"2018"},{"issue":"1","key":"10.1016\/j.bioorg.2020.103616_b0210","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12885-016-2515-7","article-title":"Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients","volume":"16","author":"Klupp","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2020.103616_b0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2407-9-188","article-title":"Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature","volume":"9","author":"K\u00f6hrmann","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2020.103616_b0220","unstructured":"Molecular Operating Environment (MOE), Chemical Computing Group, Montreal, Canada, http:\/\/www.chemcomp.com."},{"key":"10.1016\/j.bioorg.2020.103616_b0225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/6657","article-title":"Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors","volume":"6","author":"Lovejoy","year":"1999","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bioorg.2020.103616_b0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/10426509208031548","article-title":"Reactions with 6-methyl-2-thiouracil synthesis of dipyrimidino[ 2,1-b: 1',2'-c]thiazine. A new ring system","volume":"72","author":"Abdel-Fattah","year":"1992","journal-title":"Phosphorus, Sulfur Silicon Relat. Elem."},{"key":"10.1016\/j.bioorg.2020.103616_b0235","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1023\/B:RUGC.0000030401.30369.4d","article-title":"Synthesis of 2-(Pyrazol-1-yl)pyrimidine Derivatives by Cyclocondensation of Ethyl Acetoacetate (6-Methyl-4-oxo-3,4-dihydropyrimidin-2-yl)hydrazone with Aromatic Aldehydes","volume":"74","author":"Erkin","year":"2004","journal-title":"Russ. J. Gen. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0240","unstructured":"P. Nagy, I. Grobe, V. Pany, L. Fodor, Rom 63 (1978) 828; C.A 92, 41980n (1980)."},{"key":"10.1016\/j.bioorg.2020.103616_b0245","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/S0040-4020(01)81656-2","article-title":"On triazoles XI. Structure elucidation of isomeric 1,2,4-triazolopyrimidinones","volume":"43","author":"Reiter","year":"1987","journal-title":"Tetrahedron"},{"issue":"1","key":"10.1016\/j.bioorg.2020.103616_b0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4236\/ijoc.2017.71002","article-title":"Cyclocondensation reactions of hydrazonoyl chlorides with some azines: synthesis of new fused heterocycles of expected microbiological activity","volume":"7","author":"Mohamed","year":"2016","journal-title":"IJOC"},{"issue":"18","key":"10.1016\/j.bioorg.2020.103616_b0255","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1016\/j.tet.2010.03.009","article-title":"Reaction of 1-substituted 3, 5-diamino-1, 2, 4-triazoles with \u03b2-keto esters: synthesis and new rearrangement of mesoionic 3-amino-2H-[1,2,4] triazolo-[4,3-a] pyrimidin-5-ones","volume":"66","author":"Chernyshev","year":"2010","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2020.103616_b0260","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.molstruc.2017.11.066","article-title":"Synthesis, spectroscopic characterization and computational chemical study of 5-cyano-2-thiouracil derivatives as potential antimicrobial agents","volume":"1155","author":"Rizk","year":"2018","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2020.103616_b0265","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1016\/j.tetlet.2008.06.104","article-title":"Pyrazolo[3,4-d][1,2,3]triazolo[1,5-a]pyrimidine: a new ring system through Dimroth rearrangement","volume":"49","author":"Lauria","year":"2008","journal-title":"Tetrahedron Lett.."},{"key":"10.1016\/j.bioorg.2020.103616_b0270","doi-asserted-by":"crossref","unstructured":"H. Chen, O. Engkvist, T. Kogej, Compound Properties and their Influence on Drug Quality. In: Pract. Med. Chem., fourth ed., Elsevier, 2015, pp. 379\u2013393 (Chapter 15).","DOI":"10.1016\/B978-0-12-417205-0.00015-8"},{"key":"10.1016\/j.bioorg.2020.103616_b0275","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1021\/jm701255b","article-title":"Ligand binding efficiency: trends, physical basis and implications","volume":"51","author":"Reynolds","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0280","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd2796","article-title":"The influence of lead discovery strategies on the properties of drug candidates","volume":"8","author":"Keser\u00fc","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2020.103616_b0285","first-page":"31","article-title":"Lipophilicity indices for drug development","volume":"1","author":"Arnott","year":"2013","journal-title":"J. Appl. Biopharm. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2020.103616_b0290","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1021\/jm201705f","article-title":"Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein","volume":"55","author":"Jabeen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0295","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable cental nervous system drug space through the alignment of molecular properties, invitro ADME, safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2020.103616_b0300","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2020.103616_b0305","unstructured":"Molinspiration cheminformatics, https:\/\/www.molinspiration.com\/ (accessed January 13, 2019)."},{"key":"10.1016\/j.bioorg.2020.103616_b0310","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0315","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1023\/A:1020444330011","article-title":"Rate-limited steps of human oral absorption and QSAR studies","volume":"19","author":"Zhao","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2020.103616_b0320","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bioorg.2018.10.054","article-title":"Design, synthesis and pharmacological evaluation of some substituted dihydropyrimidines with L-\/T-type calcium channel blocking activities","volume":"83","author":"Teleb","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0325","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/B978-012744481-9\/50014-3","article-title":"High-speed chemistry libraries: assessment of druglikeness","author":"Polinsky","year":"2003","journal-title":"Pract. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0330","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2020.103616_b0335","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0928-0987(00)00076-2","article-title":"Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells","volume":"10","author":"Yamashita","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2020.103616_b0340","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/js9803205","article-title":"MDCK (Madin\u2013Darby canine kidney) cells: a tool for membrane permeability screening","volume":"88","author":"Irvine","year":"1999","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2020.103616_b0345","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1023\/A:1011930411574","article-title":"Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds","volume":"15","author":"Yazdanian","year":"1998","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.bioorg.2020.103616_b0350","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1023\/A:1012102522787","article-title":"In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth","volume":"14","author":"Yee","year":"1997","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2020.103616_b0355","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1745-7254.2005.00068.x","article-title":"Predictive model of blood-brain barrier penetration of organic compounds","volume":"26","author":"Ma","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2020.103616_b0360","unstructured":"PreADMET, https:\/\/preadmet.bmdrc.kr\/adme\/ (accessed August 1, 2019)."},{"key":"10.1016\/j.bioorg.2020.103616_b0365","unstructured":"Molsoft L.L.C.: Drug-Likeness and molecular property prediction, http:\/\/molsoft.com\/mprop\/ (accessed January 13, 2019)."},{"issue":"1","key":"10.1016\/j.bioorg.2020.103616_b0370","first-page":"72","article-title":"To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition","volume":"1803","author":"Jacobsen","year":"2010","journal-title":"BBA-Mol. Cell Res."},{"issue":"5","key":"10.1016\/j.bioorg.2020.103616_b0375","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cmdc.200700290","article-title":"Zinc-binding groups modulate selective inhibition of MMPs","volume":"3","author":"Agrawal","year":"2008","journal-title":"ChemMedChem: Chem. Enabling Drug Discov."},{"key":"10.1016\/j.bioorg.2020.103616_b0380","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1023\/A:1024926507658","article-title":"Unified synthetic approach to 2-substituted 6-methylisocytosines and their 5-bromo derivatives","volume":"73","author":"Erkin","year":"2003","journal-title":"Russ. J. Gen. Chem."},{"key":"10.1016\/j.bioorg.2020.103616_b0385","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejmech.2019.02.051","article-title":"Design, synthesis and biological evaluation of novel \u03b1-acyloxy carboxamides via Passerini reaction as caspase 3\/7 activators","volume":"168","author":"Salah Ayoup","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819318280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819318280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:59:53Z","timestamp":1758614393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206819318280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":77,"alternative-id":["S0045206819318280"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103616","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10\/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103616"}}